Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2026-01-21 Declaration of Voting R…
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics ASA - Minutes of Extraordinary General Meeting - Attachment: 260121-Nykode-EGM-minutes.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal 'Protocol from Extraordinary General Meeting' (Minutes) for Nykode Therapeutics ASA. It details the agenda items, resolutions passed (election of board members, remuneration, and share options), and includes official voting results, attendance lists, and share capital representation. This document is the official record of the voting results and proceedings of a general meeting, which falls under the 'Declaration of Voting Results & Voting Rights Announcements' category.
2026-01-21 English
Nykode Therapeutics ASA - Minutes of Extraordinary General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Minutes of Extraordinary General Meeting' and explicitly states that all proposed resolutions on the agenda were approved. While it mentions that the minutes are attached, the document itself serves as the official notification and declaration of the voting results from the meeting. According to the filing definitions, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the appropriate category for official results from shareholder votes at any general meeting.
2026-01-21 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is a 'Financial calendar' listing future dates for the release of various reports (Quarterly, Half-yearly, Annual) and the Annual General Meeting. It does not contain the actual financial data or reports themselves, but rather serves as an announcement of when these reports will be published. According to the 'Menu vs Meal' rule, an announcement regarding the timing or release of company reports is classified as a Report Publication Announcement (RPA).
2025-12-30 English
Nykode Therapeutics to Present Interim Data from the VB-C-03 trial at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) on March 20, 2026 - Attachment: 251219_IC
Regulatory Filings Classification · 95% confidence The document is a press release announcing an upcoming oral presentation of clinical trial data at a medical conference. It does not contain the actual financial report, audit, or regulatory filing, but rather serves as a corporate announcement regarding company activities and future event participation. As it does not fit into specific categories like earnings releases or financial reports, it falls under the general regulatory announcement category.
2025-12-19 English
Nykode Therapeutics to Present Interim Data from the VB-C-03 trial at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) on March 20, 2026
Regulatory Filings Classification · 95% confidence The document is a press release announcing an upcoming oral presentation of clinical trial data at a medical conference. It does not contain the actual financial report or the clinical data itself, but rather serves as a corporate announcement regarding future events and company activities. Since it does not fit into specific categories like earnings releases or regulatory filings for financial results, and is a general corporate announcement, it is classified as a Regulatory Filing (RNS).
2025-12-19 English
Nykode Therapeutics ASA - Notice of Extraordinary General Meeting - Attachment: 251218 - NYKD - EGM notice.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is an official 'Notice of an Extraordinary General Meeting' (Innkalling til ekstraordinær generalforsamling) for Nykode Therapeutics ASA. It outlines the agenda, voting items (election of board members, remuneration), and instructions for shareholder participation. This document is a solicitation of proxies and information provided to shareholders to prepare for a meeting, which falls under the Proxy Solicitation & Information Statement category.
2025-12-18 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.